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Cardiopulmonary exercise testing (CPET) is important for
the diﬀerential diagnosis of dyspnoea-fatigue syndromes.
The test more typically includes measurements of ventilation
(VE), carbon dioxide output (VCO2), and oxygen uptake
(VO2) at a progressively increased workload (W) until a
maximum VO2, called VO2max or VO2peak to define aerobic
exercise capacity, but steady state evaluations have utility in
some contexts. The diﬀerence in VO2max and VO2peak can
sometimes be made by the identification or not of a VO2
plateau while workload may be still increasing. However, the
information content of VO2max and VO2peak is essentially the
same, provided other criteria of maximum exercise are met,
with, importantly, a respiratory exchange ratio (RER)≥1.1.
Ventilatory reserve may be calculated at VO2peak. This is the
diﬀerence between maximum voluntary ventilation (MVV)
and VEpeak, with MVV either directly measured, or predicted
from the forced expiratory volume in 1 sec (FEV1) times 35
or 40. The ventilatory reserve normally ranges from 20 to
60 L/min, with an extreme lower limit of normal of 11 L/min,
although caution should be applied to this measure given
the unreliability of calculated MVV. Other relevant CPET
measurements are VO2 at the anaerobic threshold (VO2AT)
(RER= 1), VE/VCO2 either as a slope over the entire
CPET or, preferably, at the AT, maximum heart rate and
recovery, and the VO2-work rate relationship (ΔVO2/ΔW).
Indeed VE/VCO2 slope has been shown to be a powerful
prognostic indicator in heart failure independent of peak
VO2.
Cardiac limitation of aerobic exercise capacity is char-
acterized by decreased VO2AT, ΔVO2/ΔW and increased
VE/VCO2-slope, when heart failure is present. In these
patients, resting heart rate is increased, but maximum heart
rate and heart rate recovery are decreased (the latter to
<12 beats per min). A ventilatory limitation to exercise
capacity is characterized by a low ventilatory reserve, which
is often, but not always, attained with RER< 1. The CPET
profile of severe deconditioning resembles that of heart
failure, but with VO2max usually >20mL/kg except in the
elderly and an unremarkable VE/VCO2. The identification
of “peripheral factors” is more diﬃcult. Mitochondrial
disorders are uncommon causes of early lactic acidosis with
very low VO2max and VO2AT—along with a hyperdynamic
cardiovascular state. Muscle mass in patients with chronic
disease-associated cachexia may become insuﬃcient for a
maximal challenge of the cardiovascular system, which is
normally achieved with approximately half of the skele-
tal muscle mass (legs on the bicycle). Peripheral oxygen
extraction in heart failure has been shown to be preserved.
Therefore, in these patients VO2max is essentially maximal
cardiac output (Q-) dependent, as indicated by the Fick
equation:
VO2max = Qmax(CaO2 − CvO2), (1)
where CvO2 becomes a constant, and thus VO2max deter-
mined by maximum O2 delivery or Q × CaO2.
Many studies have reported on marked histological and
biological changes in skeletal muscle of patients with chronic
diseases, including heart failure, but measurements of max-
imum O2 extraction are few. Skeletal muscle deterioration
in cardiac or lung disease patients may be most relevant
to muscle strength or power, which is more appropriately
measured by anaerobic exercise capacity tests.
A simple, inexpensive, and safe surrogate of VO2max is the
distance walked in 6 minutes. The 6-min walk test (6MWT)
derives from the linear relationships between VO2, Q or
workload,—or speed. Like VO2max, the 6-min walk distance
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is also decreased by decreases in CaO2 as a cause of decreased
oxygen delivery and breathing reserve. The test is limited
in the less severely impaired patients by a ceiling eﬀect,
corresponding to the maximum possible speed of walking in
patients still be able to further increase VO2—but for that
purpose would have to switch to walk on a slope or running.
Demographic factors such as age, height and weight should
also be taken in to consideration of the distance walked. The
6MWT is very useful to evaluate the functional impairment
of patients, less so for the diﬀerential diagnosis of dyspnoea-
fatigue.
In the present issue of Pulmonary Medicine, these basic
exercise physiology principles are further explored by nice
series of clinical studies on patients with a variety of cardiac
and pulmonary diseases.
In the study entitled “Abnormalities of the ventilatory
equivalent for carbon dioxide in patients with chronic heart
failure” L. Ingle et al. investigated the kinetics of the
VE/VCO2 ratio during an incremental exercise testing follow-
ing a modified Bruce protocol in a large series of 423 patients
with chronic heart failure compared to 78 healthy controls.
They showed that the nadir of the VE/VCO2 in patients with
heart failure occurred earlier, and that this was of prognostic
relevance. These results add to previously known prognostic
value of increased VE/VCO2-slope in heart failure. The
authors’ interpretation of the findings is that a shorter time to
VE/VCO2nadir reflects earlier onset of the non-CO2 stimulus
to ventilation in patients with chronic heart failure. This is
possible. However, the time to VE/VCO2nadir was decreased
in proportion to the decreased exercise duration, VO2AT
or VO2peak, all at around 60% of measured in the controls,
indicating an important intrinsic contribution of aerobic
exercise capacity, known as another determinant of survival
in heart failure.
The study by R. L. Chura et al. “Test-retest reliability
and physiological responses associated with the steep ramp
anaerobic test in patients with COPD” provides robust data
on the reproducibility of a very steep incremental exercise
protocol (25W per 10 s) in 11 COPD patients. The Steep
Ramp Anaerobic test (SRAT) aimes at a measurement of
anaerobic exercise capacity, and, as such, was compared
by the authors to the more classically known 30s-Wingate
Anaerobic Test (WAT). The patients also performed a CPET.
Both SRAT and WAT showed a good reproducibility at 1-
2 days intervals. Maximum power output was 157W on
the SRAT, compared to 231W on the WAT and 66W on
the CPET, but metabolic and ventilatory responses were
similar. The FEV1 of the patients was on average of 1 L,
allowing to estimate a MVV of 40 L/min. The VEmax was on
average 40 L/min during the three exercise tests, indicating
that the three tests exhaused the ventilatory reserve of the
patients. Because the peak work output was the highest at
the maximum achieved VO2 with the SRAT, the authors
concluded about the superiority of this test over the WAT
to determine anaerobic exercise capacity. This makes a lot of
sense. Furthermore, the higher power output with the SRAT
compared to the WAT at similar VO2 probably reveals more
specific measurement of purely alactic anaerobic exercise
capacity. This important study will hopefully draw attention
to the importance of anaerobic exercise testing in the
evaluation of patients with cardiac and pulmonary diseases.
In the article “Cardiopulmonary exercise testing in lung
transplantation: a review” K. A. Dudley and S. El-Chemaly
review published data on the role of CPET in the assessment
of appropriateness of listing for lung transplantation as well
of posttransplant outcome in patients with various forms of
lung disease. The lung allocation score does not currently
include CPET variables, but exercise capacity solely deter-
mined by a 6MWT. The review confirmed the previously
known prognostic relevance of the 6MWT for patients await-
ing transplantation. In these patients, the 6MWT was supe-
rior to spirometry in the prediction of 6-month mortality.
However, how pretransplant 6MWT relates to posttransplant
functional state and prognosis remains unclear. The reason
why CPET variables are currently not components of the
lung allocation score is in the insuﬃcient evidence derived
from limited size studies evaluating only specific respiratory
pathologies and type of transplant, thus with findings that
are diﬃcult to extrtapolate to other patients waiting for
transplantation. Data from posttransplant patients reveal
some functional improvement with, however, still significant
reduction in exercise tolerance. This does not appear to
be limited by the pulmonary function, therefore pointing
towards peripheral mechanisms of reduced functional capac-
ity. Despite the need for more systematic studies in this field,
the authors conclude that, based on the existing data, CPET
carries prognostic information beyond that of pulmonary
function tests and 6-minute-walk distance suggesting a role
of CPET in pretransplant and possibly also posttransplant
assessment.
The study “Predicted aerobic exercise capacity of asthmatic
children: a research study from clinical origin” by L. Lochte
compared longitudinally the predicted aerobic exercise
capacity based on submaximal exercise testing in 28 asth-
matic children compared to 28 controls during 10 months.
There were also physical activity and asthma questionnaires.
The predicted aerobic exercise capacity test consisted in
5min continuous running on a tredmill at a running speed
adjusted to maintain a stable submaximal heart rate of
170–180 bpm. The estimation of VO2max was based on
previously reported weight-adjusted VO2, running speed
and heart rate, and VO2 extrapolated from the diﬀerence
between maximum and submaximum heart rates. This is an
adaptation of the Astrand test, based on the same rationale
that any further increase in VO2 (or Q) at a submaximum
level of exercise is exclusively heart rate determined. Physical
activity as evaluated by questionnaires was well correlated
to estimated VO2max—and age. The results showed lower
predicted aerobic exercise capacity in asthmatic children,
without this being related to asthma severity or exercise
induced asthma, but there was improvement over time. The
reasons for decreased fitness in young asthmatics are unclear,
but it might be deconditioning rather than insuﬃcient
asthma control. The study underscores the importance of
monitoring physical activity in addition to lung function in
children with asthma.
The study “The impact of pulmonary arterial pressure
on exercise capacity in mild-to-moderate cystic fibrosis: a case
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control study” by K. Manika et al. explored the impact
of systolic pulmonary artery pressure (PASP) measured
by echocardiography before and immediately after testing
on exercise capacity in 17 patients with mild-to-moderate
cystic fibrosis without pulmonary hypertension and in 10
controls. The patients hads higher postexercise PASP and
lower VO2peak, VO2AT, and peak O2 pulse than the controls.
The change in PASP was strongly correlated to parameters
of exercise capacity in the patients, not in the controls. The
authors conclude that pulmonary vascular disease might
contribute to decreased exercise capacity in patients with
cystic fibrosis. It may be noted that the postexercise PASP
were not higher than normal, and the diﬀerence between
patients and controls, though significant, was of a few
mmHg, thus in the range of the error of measurement.
However, the patients had an average ventilatory reserve of
around 40 L/min at maximum exercise, the maximum RER
was of 1.19, not diﬀerent from the controls and the patients
with the highest PASP also had a higher VE/VCO2. It is thus
possible that pulmonary vascular disease contributes to the
limitation of exercise capacity in patients with cystic fibrosis.
Further studies on a larger number of patients with more
comprehensive measurements of the pulmonary circulation
will be needed to prove it.
The study “Validity of reporting oxygen uptake eﬃciency
slope from submaximal exercise using respiratory exchange
ratio as secondary criterion” by W. Williamson et al. inves-
tigated the VO2 eﬃciency slope, or rate of change in VO2
per rate of change in VE, in 100 healthy volunteers during a
ramped treadmill protocol from data truncated to RER levels
from 0.85 to 1.2. The slope increased significantly from low-
to-moderate intensity exercise and was highest at a RER of 1,
decreasing at higher values. The O2 eﬃciency slope has been
previously reported to be a valid and reproducible marker of
function and prognosis as VO2peak. The present results show
that VO2 slope is not constant during an incremental CPET
and probably optimally measured at the RER of 1. How this
tighter definition of the VO2 slope compares with VO2AT,
VE/VCO2, ΔVO2/W , and chronotropic incompetence in the
evaluation of patients with cardiac or pulmonary diseases
will have to be investigated in further studies.
In summary, for those of us interested in a better under-
standing of the dyspnoea-fatigue symptoms of our patients,
CPET is a remarkable tool. It generates lots of variables
that need integration into pathophysiological reasoning and
pretest clinical probability assessments. More work is needed
for the integration of the CPET variables into validated
decision trees and recommendations. This is an exciting area,
still open for a lot more investigation and progress. The series
papers published in this issue of Pulmonary Medicine are
altogether an important step in the good direction.
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